Trial Profile

Phase I Study of APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 23 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Eprenetapopt (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions; Therapeutic Use
Sponsors Aprea Therapeutics

Most Recent Events

18 Jan 2022 Status changed from active, no longer recruiting to completed.
14 Dec 2021 Results (n=47; data cutoff date of 22 June 2021) assessing the safety and preliminary efficacy of eprenetapopt in combination with venetoclax and azacitidine in TP53 mutant acute myeloid leukemia, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
14 Dec 2021 According to an Aprea media release, results from this trial were presented at the 63rd American Society of Hematology Annual Meeting (ASH) 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com